Vera Therapeutics (VERA) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 3[1], 3 Phase 2[2].
Trial NCT04716231[4] evaluates Atacicept in IgA Nephropathy with a target enrollment of 376 participants.
VERA has 2 Form 4 insider filings recorded at the SEC in the past 30 days[5].